Search results for "Systemic."

showing 10 items of 756 documents

Traps N' Clots: NET-Mediated Thrombosis and Related Diseases.

2020

medicine.medical_specialtyHypertension PulmonaryArterial Occlusive DiseasesGastroenterologyExtracellular TrapsAutoimmune DiseasesTranslational Research BiomedicalMiceInternal medicineNeoplasmsThromboembolismmedicineAnimalsHumansInflammationVenous Thrombosisbusiness.industryThrombosisHematologymedicine.diseasePlatelet ActivationThrombosisSystemic Inflammatory Response SyndromeEndothelium VascularbusinessForecastingThrombosis and haemostasis
researchProduct

Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis…

2022

Abstract Although each autoimmune disease is associated with specific tissue or organ damage, rheumatic diseases share a pro-inflammatory pattern that might increase cardiovascular risk. Retrospective and prospective studies on patients affected by systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) highlighted the concept of “accelerated atherosclerosis”. Therefore, the purpose of this systematic review and meta-analysis is the assessment of symptomatic or asymptomatic cardiovascular events among patients with rheumatic diseases as RA and SLE. The literature research obtained all manuscripts published in the English language between 2015 and 2019 for a total of 2355 manuscript…

medicine.medical_specialtyImmunologyDiseaseAsymptomaticArthritis RheumatoidRisk FactorsInternal medicinemedicineHumansLupus Erythematosus SystemicImmunology and AllergyProspective StudiesProspective cohort studyRetrospective StudiesAutoimmune diseasebusiness.industryIncidence (epidemiology)medicine.diseaseCardiovascular DiseasesHeart Disease Risk FactorsAge Cardiovascular events Metaanalysis Rheumatoid arthritis Risk Systemic lupus erythematosusMeta-analysisRheumatoid arthritisInclusion and exclusion criteriamedicine.symptombusinessAutoimmunity Reviews
researchProduct

Role of cytokines and oxidative stress in the pathophysiology of acute pancreatitis: therapeutical implications.

2002

Abstract Severe acute pancreatitis causes a high incidence of mortality due to the systemic inflammatory response syndrome leading to multiple organ failure. At present, there is no treatment against severe acute pancreatitis, other than supportive critical care. The relationship between pancreatic injury and the uncontrolled systemic response is not completely understood. Nevertheless, experimental and clinical evidences have shown that pro-inflammatory cytokines and oxidative stress are critically involved in the development of local and systemic complications associated with severe acute pancreatitis. Serum levels of pro-inflammatory cytokines, such as TNF-alpha and IL-1beta, increase du…

medicine.medical_specialtyImmunologyInflammationmedicine.disease_causePentoxifyllinechemistry.chemical_compoundInternal medicinemedicineImmunology and AllergyHumansXanthine oxidasePharmacologyInflammationbusiness.industryPneumoniamedicine.diseaseSystemic inflammatory response syndromeOxidative StressEndocrinologymedicine.anatomical_structurechemistryPancreatitisImmunologyAcute DiseaseAcute pancreatitisCytokinesPancreatic injurymedicine.symptombusinessPancreasOxidative stressmedicine.drugCurrent drug targets. Inflammation and allergy
researchProduct

The skin in autoimmune diseases-Unmet needs.

2016

Treatment of skin manifestations in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and dermatomyositis (DM) is based on the results of only few randomized controlled trials. The first-line treatment for disfiguring and widespread cutaneous involvement in SLE is antimalarials, but some patients are therapy resistant. Recently, the monoclonal antibody belimumab was approved for SLE as an adjunct therapy for patients with autoantibody-positive disease who despite standard therapy show high disease activity, intolerance of other treatments, or an unacceptably high need for corticosteroids. However, a validated skin score has not been used to confirm the efficacy of belimumab on m…

medicine.medical_specialtyImmunologyMucocutaneous zoneDiseaseSeverity of Illness IndexDermatomyositislaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineImmunology and AllergyHumansLupus Erythematosus SystemicRandomized Controlled Trials as TopicSkin030203 arthritis & rheumatologyAutoimmune diseaseWound HealingScleroderma Systemicintegumentary systembusiness.industryDermatomyositismedicine.diseaseDermatologyBelimumabDiscontinuationImmunologybusinessProgressive diseaseImmunosuppressive Agentsmedicine.drugAutoimmunity reviews
researchProduct

Positive Airway Pressure Treatment Reduces Glycated Hemoglobin (HbA1c) Levels in Obstructive Sleep Apnea Patients: Longitudinal Data from the Esada

2019

European-Respiratory-Society (ERS) International Congress -- SEP 28-OCT 02, 2019 -- Madrid, SPAIN

medicine.medical_specialtyLongitudinal dataGastroenterologyComorbidities03 medical and health sciencesHba1c levelchemistry.chemical_compound0302 clinical medicineDiabetes mellitusInternal medicinePositive airway pressuremedicine030212 general & internal medicinebusiness.industryType 2 Diabetes MellitusSleep apneaSystemic effectmedicine.diseaserespiratory tract diseasesObstructive sleep apnea030228 respiratory systemApnea–hypopnea indexchemistryCardiologyGlycated hemoglobinbusinessBody mass indexTurkish Thoracic Journal
researchProduct

0347: Beneficial cardiovascular effects of O-GlcNAc stimulation in early phase of septic shock

2016

BackgroundO-GlcNAcylation, a post-translational modification, is the end product of the hexosamine biosynthetic pathway (HBP). Recent studies showed beneficial effects of its increase in acute pathologies, such as hemorrhagic shock. We postulated that increase in total protein OGlcNAcylation at the early phase of septic shock, a systemic inflammation associated with a cardiovascular dysfunction, could improve cardiovascular function and reduce mortality.MethodsTo induce an endotoxemic shock, rats (n=6-8) received iv either lipopolysaccharide (LPS, 5mg/kg) or saline (CTRL). After 1 h, fluid resuscitation (FR,15mL/kg of colloid, iv) was associated or not with HBP substrate: glucosamine (GlcN,…

medicine.medical_specialtyMean arterial pressureResuscitationTroponin TLipopolysaccharideSeptic shockbusiness.industryStimulationPharmacologymedicine.diseaseSystemic inflammationSurgerychemistry.chemical_compoundchemistryShock (circulatory)medicinelipids (amino acids peptides and proteins)medicine.symptomCardiology and Cardiovascular MedicinebusinessArchives of Cardiovascular Diseases Supplements
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic L…

2019

OBJECTIVE: To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure response to therapy in childhood-onset systemic lupus erythematosus (cSLE), with a focus on clinically relevant improvement (CRIc SLE ). METHODS: Pediatric nephrology and rheumatology subspecialists (n = 213) experienced in cSLE management were invited to define CRIc SLE and rate a total of 433 unique patient profiles for the presence/absence of CRIc SLE . Patient profiles included the following cSLE core response variables (CRVs): global assessment of patient well-being (patient-global), physician assessment of cSLE activity (MD-global), disease activity index score (here, we used the Systemic Lupus Eryt…

medicine.medical_specialtyOutcome AssessmentHealth Care/methodsAdolescentDelphi TechniqueAntirheumatic Agents/therapeutic useSeverity of Illness IndexChild healthArticle03 medical and health sciences0302 clinical medicineRheumatologyInternal medicineSeverity of illnessOutcome Assessment Health CaremedicinePediatric nephrologyHumansLupus Erythematosus Systemicskin and connective tissue diseasesChild030203 arthritis & rheumatologySystemic lupus erythematosusLupus erythematosusLupus ErythematosusReceiver operating characteristicbusiness.industryConsensus conferencechildhood-onset systemic lupus erythematosusOutcome Assessment Health Care/methodsmedicine.diseaseRheumatologyRheumatologySystemic lupus erythematosusautoimmune inflammatory diseaseAntirheumatic AgentsLupus Erythematosus Systemic/drug therapySystemic/drug therapybusinessAlgorithmsArthritis Care and Research
researchProduct

Solid organ transplantation for non-TTR hereditary amyloidosis: report from the 1st International Workshop on the Hereditary Renal Amyloidoses.

2012

Fibrinogen A α-chain (AFib) and apolipoprotein AI (AApoAI) amyloidosis due to variants in the AFib and ApoAI genes are the most common types of hereditary amyloidosis in Europe and the United States. Liver is the exclusive source of the aberrant amyloidogenic protein in AFib and responsible for supplying approximately half of the circulating variant ApoAI. Nephrotic syndrome and renal impairment due to renal amyloidosis are common disease manifestations; however, recent research provides evidence to support a more diverse and systemic disease phenotype, which in turn has implications in the management of the hereditary amyloidoses with solid organ transplantation and, in particular, liver t…

medicine.medical_specialtyPathologySystemic diseasemedicine.medical_treatmentLiver transplantationOrgan transplantationRenal amyloidosisInternal MedicineMedicineHumansbiologyApolipoprotein A-Ibusiness.industryAmyloidosisFibrinogenOrgan Transplantationmedicine.diseaseLiver TransplantationTransplantationTransthyretinTreatment OutcomeImmunologybiology.proteinbusinessNephrotic syndromeAmyloidosis FamilialAmyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
researchProduct

SUBFRACTIONS AND SUBPOPULATIONS OF HDL: AN UPDATE

2014

High-density lipoproteins (HDL) are classified as atheroprotective because they are involved in transport of cholesterol to the liver, known as "reverse cholesterol transport (RCT)" exerting antioxidant and anti-inflammatory activities. There is also evidence for cytoprotective, vasodilatory, antithrombotic, and anti-infectious activities for these lipoproteins. HDLs are known by structural, metabolic and biologic heterogeneity. Thus, different methods are able to distinguish several subclasses of HDL. Different separation techniques appear to support different HDL fractions as being atheroprotective or related with lower cardiovascular (CV) risk. However, HDL particles are not always prote…

medicine.medical_specialtyPharmacologyBiologySystemic inflammationBiochemistrychemistry.chemical_compoundRisk FactorsInternal medicineDrug DiscoveryAntithromboticmedicineAnimalsHumansHdl functionalityPharmacologyCholesterolOrganic ChemistryReverse cholesterol transportBiomarker (cell)EndocrinologychemistryCardiovascular DiseasesMolecular MedicineSeparation methodlipids (amino acids peptides and proteins)Hdl subfractionscardiovascular risk electrophoresis high-density lipoprotein nuclear magnetic resonance proteome subclasses subfractions ultracentrifugation.medicine.symptomLipoproteins HDL
researchProduct